Print Page     Close Window     
6-K
MESOBLAST LTD filed this Form 6-K on 08/31/2018
Entire Document
 

 

 

Consolidated Income Statement

 

 

 

(unaudited)

 

 

(audited)

 

 

 

Three Months Ended June 30,

 

 

Year Ended June 30,

 

(in U.S. dollars, in thousands, except per share amount)

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenue

 

 

1,700

 

 

 

566

 

 

 

17,341

 

 

 

2,412

 

Research & development

 

 

(17,539

)

 

 

(15,939

)

 

 

(65,927

)

 

 

(58,914

)

Manufacturing commercialization

 

 

(2,121

)

 

 

(1,150

)

 

 

(5,508

)

 

 

(12,065

)

Management and administration

 

 

(5,219

)

 

 

(7,148

)

 

 

(21,907

)

 

 

(23,007

)

Fair value remeasurement of contingent consideration

 

 

2,661

 

 

 

(7,908

)

 

 

10,541

 

 

 

(130

)

Other operating income and expenses

 

 

69

 

 

 

321

 

 

 

1,312

 

 

 

1,489

 

Finance costs

 

 

(1,406

)

 

 

 

 

 

(1,829

)

 

 

 

Impairment of intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income tax

 

 

(21,855

)

 

 

(31,258

)

 

 

(65,977

)

 

 

(90,215

)

Income tax benefit/(expense)

 

 

1,021

 

 

 

4,076

 

 

 

30,687

 

 

 

13,400

 

Loss attributable to the owners of Mesoblast Limited

 

 

(20,834

)

 

 

(27,182

)

 

 

(35,290

)

 

 

(76,815

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Losses per share from continuing operations attributable

   to the ordinary equity holders of the Group:

 

Cents

 

 

Cents

 

 

Cents

 

 

Cents

 

Basic - losses per share

 

 

(4.39

)

 

 

(6.34

)

 

 

(7.58

)

 

 

(19.25

)

Diluted - losses per share

 

 

(4.39

)

 

 

(6.34

)

 

 

(7.58

)

 

 

(19.25

)

 

 

Consolidated Statement of Comprehensive Income

 

 

 

(unaudited)

 

 

(audited)

 

 

 

Three Months Ended June 30,

 

 

Year Ended June 30,

 

(in U.S. dollars, in thousands)

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Loss for the year

 

 

(20,834

)

 

 

(27,182

)

 

 

(35,290

)

 

 

(76,815

)

Other comprehensive (loss)/income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Items that may be reclassified to profit and loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Changes in the fair value of available-for-sale financial

   assets

 

 

183

 

 

 

86

 

 

 

324

 

 

 

31

 

Exchange differences on translation of foreign operations

 

 

(334

)

 

 

(52

)

 

 

(903

)

 

 

316

 

Other comprehensive (loss)/income for the period,

   net of tax

 

 

(151

)

 

 

34

 

 

 

(579

)

 

 

347

 

Total comprehensive losses attributable to the

   owners of Mesoblast Limited

 

 

(20,985

)

 

 

(27,148

)

 

 

(35,869

)

 

 

(76,468

)


 

 

Mesoblast Limited
ABN 68 109 431 870

 

www.mesoblast.com

Corporate Headquarters

Level 38

55 Collins Street

Melbourne 3000

Victoria Australia

 

T +61 3 9639 6036

F +61 3 9639 6030

United States Operations

505 Fifth Avenue

Third Floor

New York, NY 10017

USA

 

T +1 212 880 2060

F +1 212 880 2061

Asia

20 Biopolis Way

#05-01 Centros

Biopreneur 3

SINGAPORE 138668

 

T +65 6570 0635

F +65 6570 0176

 

 

 

 

 

 

 

 

 

 

 

 

 



Copyright © 2015 Mesoblast Inc.